Identification

Name
Bupranolol
Accession Number
DB08808
Type
Small Molecule
Groups
Approved
Description

Bupranolol is a non-selective beta blocker without intrinsic sympathomimetic activity (ISA), but with strong membrane stabilizing activity. Its potency is similar to "propranolol":http://www.drugbank.ca/drugs/DB00571.

Structure
Thumb
Synonyms
  • Bupranol
Product Ingredients
IngredientUNIICASInChI Key
Bupranolol hydrochlorideDTC2G3GDPL15148-80-8WJUUZHQWGKSLIJ-UHFFFAOYSA-N
International/Other Brands
Betadrenol (Desma) / Ophtorenin (Winzer (Germany))
Categories
UNII
858YGI5PIT
CAS number
14556-46-8
Weight
Average: 271.783
Monoisotopic: 271.13390666
Chemical Formula
C14H22ClNO2
InChI Key
HQIRNZOQPUAHHV-UHFFFAOYSA-N
InChI
InChI=1S/C14H22ClNO2/c1-10-5-6-12(15)13(7-10)18-9-11(17)8-16-14(2,3)4/h5-7,11,16-17H,8-9H2,1-4H3
IUPAC Name
1-(tert-butylamino)-3-(2-chloro-5-methylphenoxy)propan-2-ol
SMILES
CC1=CC(OCC(O)CNC(C)(C)C)=C(Cl)C=C1

Pharmacology

Indication

Used to manage hypertension and tachycardia. Also used to treat glaucoma.

Structured Indications
Not Available
Pharmacodynamics

Bupranolol is a competitive, nonselective beta-blocker similar to propanolol without intrinsic sympathomimetic activity.

Mechanism of action

Bupranolol competes with sympathomimetic neurotransmitters such as catecholamines for binding at beta(1)-adrenergic receptors in the heart, inhibiting sympathetic stimulation. This results in a reduction in resting heart rate, cardiac output, systolic and diastolic blood pressure, and reflex orthostatic hypotension.

TargetActionsOrganism
ABeta-1 adrenergic receptor
antagonist
Human
UBeta-2 adrenergic receptor
antagonist
Human
UBeta-3 adrenergic receptor
antagonist
Human
Absorption

Quickly and completely absorbed from the gut with less than 10% oral bioavailability.

Volume of distribution
Not Available
Protein binding

76%

Metabolism

Over 90% undergo first-pass metabolism. The main metabolite is carboxybupranolol, 4-chloro-3-[3-(1,1-dimethylethylamino)-2-hydroxy-propyloxy]benzoic acid, of which 88% are eliminated renally within 24 hours.

Route of elimination
Not Available
Half life

2-4 hours

Clearance
Not Available
Toxicity

Symptoms of overdose include bradycardia, cardiac failure, hypotension, and brochospasm.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Bupranolol Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Bupranolol.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Bupranolol.Experimental
AcebutololAcebutolol may increase the hypotensive activities of Bupranolol.Approved
AceclofenacAceclofenac may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
AcemetacinAcemetacin may decrease the antihypertensive activities of Bupranolol.Approved
AcepromazineAcepromazine may increase the hypotensive activities of Bupranolol.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Bupranolol.Approved
AcetohexamideBupranolol may increase the hypoglycemic activities of Acetohexamide.Investigational, Withdrawn
AcetylcholineThe risk or severity of adverse effects can be increased when Bupranolol is combined with Acetylcholine.Approved
AcetyldigitoxinBupranolol may increase the bradycardic activities of Acetyldigitoxin.Approved
AcetyldigoxinBupranolol may increase the bradycardic activities of Acetyldigoxin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Bupranolol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Bupranolol.Approved
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Experimental, Investigational
AlaproclateThe serum concentration of Bupranolol can be increased when it is combined with Alaproclate.Experimental
AlclofenacAlclofenac may decrease the antihypertensive activities of Bupranolol.Approved, Withdrawn
AlfentanilAlfentanil may increase the bradycardic activities of Bupranolol.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Bupranolol.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Bupranolol.Approved, Vet Approved
AliskirenBupranolol may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlminoprofenAlminoprofen may decrease the antihypertensive activities of Bupranolol.Experimental
AlprenololAlprenolol may increase the hypotensive activities of Bupranolol.Approved, Withdrawn
AmbenoniumAmbenonium may increase the bradycardic activities of Bupranolol.Approved
AmbrisentanBupranolol may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Ambroxol acefyllinateBupranolol may decrease the bronchodilatory activities of Ambroxol acefyllinate.Experimental, Investigational
AmifostineBupranolol may increase the hypotensive activities of Amifostine.Approved, Investigational
AminophyllineBupranolol may decrease the bronchodilatory activities of Aminophylline.Approved
AmiodaroneAmiodarone may increase the bradycardic activities of Bupranolol.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Bupranolol.Approved
AmobarbitalThe serum concentration of Bupranolol can be decreased when it is combined with Amobarbital.Approved, Illicit
AmodiaquineThe metabolism of Bupranolol can be decreased when combined with Amodiaquine.Approved, Investigational
AndrographolideAndrographolide may decrease the antihypertensive activities of Bupranolol.Investigational
AnisodamineAnisodamine may decrease the antihypertensive activities of Bupranolol.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Bupranolol.Approved
ApocyninApocynin may decrease the antihypertensive activities of Bupranolol.Investigational
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved, Investigational
ApremilastApremilast may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
ArbutamineBupranolol may decrease the bronchodilatory activities of Arbutamine.Approved
ArecolineThe risk or severity of adverse effects can be increased when Bupranolol is combined with Arecoline.Experimental
ArformoterolBupranolol may decrease the bronchodilatory activities of Arformoterol.Approved, Investigational
AtenololAtenolol may increase the hypotensive activities of Bupranolol.Approved
AzapropazoneAzapropazone may decrease the antihypertensive activities of Bupranolol.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Bupranolol.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
BambuterolBupranolol may decrease the bronchodilatory activities of Bambuterol.Approved, Investigational
BarbexacloneThe serum concentration of Bupranolol can be decreased when it is combined with Barbexaclone.Experimental
BarbitalThe serum concentration of Bupranolol can be decreased when it is combined with Barbital.Illicit
BenazeprilBenazepril may increase the hypotensive activities of Bupranolol.Approved, Investigational
BendazacBendazac may decrease the antihypertensive activities of Bupranolol.Experimental
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Bupranolol.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Bupranolol.Withdrawn
BenorilateBenorilate may decrease the antihypertensive activities of Bupranolol.Experimental
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Bupranolol.Withdrawn
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved, Illicit
BepridilBepridil may increase the hypotensive activities of Bupranolol.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Bupranolol.Approved
BethanecholThe risk or severity of adverse effects can be increased when Bupranolol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
BevoniumBevonium may decrease the antihypertensive activities of Bupranolol.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Bupranolol.Experimental
BimatoprostBimatoprost may increase the hypotensive activities of Bupranolol.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Bupranolol.Approved
BL-1020BL-1020 may increase the hypotensive activities of Bupranolol.Investigational
BosentanBosentan may increase the hypotensive activities of Bupranolol.Approved, Investigational
BQ-123Bupranolol may increase the hypotensive activities of BQ-123.Investigational
BretyliumBretylium may increase the hypotensive activities of Bupranolol.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Bupranolol.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Bupranolol.Experimental
BromfenacBromfenac may decrease the antihypertensive activities of Bupranolol.Approved
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Bupranolol.Investigational
BucindololBupranolol may increase the orthostatic hypotensive activities of Bucindolol.Investigational
BufexamacBufexamac may decrease the antihypertensive activities of Bupranolol.Experimental
BumadizoneBumadizone may decrease the antihypertensive activities of Bupranolol.Experimental
BunazosinBupranolol may increase the orthostatic hypotensive activities of Bunazosin.Investigational
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Bupranolol.Approved, Investigational
CabergolineBupranolol may increase the vasoconstricting activities of Cabergoline.Approved
CadralazineCadralazine may increase the hypotensive activities of Bupranolol.Experimental
CafedrineBupranolol may increase the hypotensive activities of Cafedrine.Investigational
Candesartan cilexetilCandesartan may increase the hypotensive activities of Bupranolol.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Bupranolol.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Bupranolol.Approved
CarbacholThe risk or severity of adverse effects can be increased when Bupranolol is combined with Carbachol.Approved
Carbaspirin calciumCarbaspirin calcium may decrease the antihypertensive activities of Bupranolol.Experimental, Investigational
CarbutamideBupranolol may increase the hypoglycemic activities of Carbutamide.Experimental
CaroxazoneCaroxazone may increase the hypotensive activities of Bupranolol.Withdrawn
CarprofenCarprofen may decrease the antihypertensive activities of Bupranolol.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the hypotensive activities of Bupranolol.Approved
CarvedilolBupranolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Bupranolol.Experimental
CelecoxibCelecoxib may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
CeliprololCeliprolol may increase the hypotensive activities of Bupranolol.Approved, Investigational
CevimelineThe risk or severity of adverse effects can be increased when Bupranolol is combined with Cevimeline.Approved
ChloroquineThe metabolism of Bupranolol can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Bupranolol.Approved, Vet Approved
ChlorproethazineChlorproethazine may increase the hypotensive activities of Bupranolol.Experimental
ChlorpromazineChlorpromazine may increase the hypotensive activities of Bupranolol.Approved, Vet Approved
ChlorpropamideBupranolol may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Bupranolol.Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the antihypertensive activities of Bupranolol.Approved
CicletanineBupranolol may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilCilazapril may increase the hypotensive activities of Bupranolol.Approved
ClenbuterolBupranolol may decrease the bronchodilatory activities of Clenbuterol.Approved, Investigational, Vet Approved
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Bupranolol.Approved
CloranololBupranolol may increase the hypotensive activities of Cloranolol.Experimental
CoumaphosCoumaphos may increase the bradycardic activities of Bupranolol.Vet Approved
CryptenamineCryptenamine may increase the hypotensive activities of Bupranolol.Approved
CurcuminCurcumin may decrease the antihypertensive activities of Bupranolol.Investigational
CyclopenthiazideBupranolol may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideCyclothiazide may increase the hypotensive activities of Bupranolol.Approved
CymarinBupranolol may increase the bradycardic activities of Cymarin.Experimental
D-LimoneneD-Limonene may decrease the antihypertensive activities of Bupranolol.Investigational
DapoxetineThe serum concentration of Bupranolol can be increased when it is combined with Dapoxetine.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Bupranolol.Approved, Investigational
DecamethoniumDecamethonium may increase the bradycardic activities of Bupranolol.Approved
DelaprilBupranolol may increase the hypotensive activities of Delapril.Experimental
DemecariumDemecarium may increase the bradycardic activities of Bupranolol.Approved
DeserpidineBupranolol may increase the hypotensive activities of Deserpidine.Approved
DeslanosideBupranolol may increase the bradycardic activities of Deslanoside.Approved
DesvenlafaxineThe serum concentration of Bupranolol can be increased when it is combined with Desvenlafaxine.Approved
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Bupranolol.Approved
DichlorvosDichlorvos may increase the bradycardic activities of Bupranolol.Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Bupranolol.Approved, Vet Approved
diethylnorsperminediethylnorspermine may increase the hypotensive activities of Bupranolol.Investigational
DifenpiramideDifenpiramide may decrease the antihypertensive activities of Bupranolol.Experimental
DiflunisalDiflunisal may decrease the antihypertensive activities of Bupranolol.Approved
DigitoxinBupranolol may increase the bradycardic activities of Digitoxin.Approved, Investigational
DigoxinBupranolol may increase the bradycardic activities of Digoxin.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Bupranolol.Investigational
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
DiltiazemDiltiazem may increase the hypotensive activities of Bupranolol.Approved
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Bupranolol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Bupranolol.Approved
DistigmineDistigmine may increase the bradycardic activities of Bupranolol.Experimental
DobutamineBupranolol may decrease the bronchodilatory activities of Dobutamine.Approved
DonepezilDonepezil may increase the bradycardic activities of Bupranolol.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Bupranolol.Approved
DoxazosinBupranolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
DronedaroneDronedarone may increase the bradycardic activities of Bupranolol.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Bupranolol.Approved
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved, Investigational
DuloxetineThe serum concentration of Bupranolol can be increased when it is combined with Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Bupranolol.Investigational
DyphyllineBupranolol may decrease the bronchodilatory activities of Dyphylline.Approved
E-6201E-6201 may decrease the antihypertensive activities of Bupranolol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Bupranolol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Bupranolol.Approved
EfonidipineBupranolol may increase the hypotensive activities of Efonidipine.Approved
EnalaprilEnalapril may increase the hypotensive activities of Bupranolol.Approved, Vet Approved
EnalaprilatBupranolol may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Bupranolol.Experimental
EpanololBupranolol may increase the hypotensive activities of Epanolol.Experimental
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved, Nutraceutical, Withdrawn
EpibatidineThe risk or severity of adverse effects can be increased when Bupranolol is combined with Epibatidine.Experimental
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Bupranolol.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Bupranolol.Approved
EprosartanEprosartan may increase the hypotensive activities of Bupranolol.Approved
Ergoloid mesylateBupranolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovineBupranolol may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
EthenzamideEthenzamide may decrease the antihypertensive activities of Bupranolol.Experimental
EtodolacEtodolac may decrease the antihypertensive activities of Bupranolol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
EtoperidoneThe serum concentration of Bupranolol can be increased when it is combined with Etoperidone.Withdrawn
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
exisulindexisulind may decrease the antihypertensive activities of Bupranolol.Investigational
FelbinacFelbinac may decrease the antihypertensive activities of Bupranolol.Experimental
FelodipineFelodipine may increase the hypotensive activities of Bupranolol.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Bupranolol.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Bupranolol.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Bupranolol.Approved
FenoterolBupranolol may decrease the bronchodilatory activities of Fenoterol.Approved, Investigational
FentanylFentanyl may increase the bradycardic activities of Bupranolol.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Bupranolol.Vet Approved
FentiazacFentiazac may decrease the antihypertensive activities of Bupranolol.Experimental
FeprazoneFeprazone may decrease the antihypertensive activities of Bupranolol.Experimental
Ferulic acidFerulic acid may increase the hypotensive activities of Bupranolol.Experimental
FingolimodBupranolol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Bupranolol.Approved, Withdrawn
FlunixinFlunixin may decrease the antihypertensive activities of Bupranolol.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the antihypertensive activities of Bupranolol.Experimental
FluoxetineThe serum concentration of Bupranolol can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FluphenazineFluphenazine may increase the hypotensive activities of Bupranolol.Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
FormoterolBupranolol may decrease the bronchodilatory activities of Formoterol.Approved, Investigational
FosinoprilFosinopril may increase the hypotensive activities of Bupranolol.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Bupranolol.Approved, Investigational, Vet Approved
GalantamineGalantamine may increase the bradycardic activities of Bupranolol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Bupranolol.Approved
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Bupranolol.Approved, Investigational, Nutraceutical
GitoformateBupranolol may increase the bradycardic activities of Gitoformate.Experimental
GlibornurideBupranolol may increase the hypoglycemic activities of Glibornuride.Investigational, Withdrawn
GliclazideBupranolol may increase the hypoglycemic activities of Gliclazide.Approved
GlipizideBupranolol may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneBupranolol may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
GlisoxepideBupranolol may increase the hypoglycemic activities of Glisoxepide.Approved, Investigational
GlyburideBupranolol may increase the hypoglycemic activities of Glyburide.Approved
GTS-21The risk or severity of adverse effects can be increased when Bupranolol is combined with GTS-21.Investigational
GuacetisalGuacetisal may decrease the antihypertensive activities of Bupranolol.Experimental
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Bupranolol.Approved
GuanazodineBupranolol may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Bupranolol.Approved
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved, Investigational
GuanoclorBupranolol may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzBupranolol may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanBupranolol may increase the hypotensive activities of Guanoxan.Experimental
HarmalineHarmaline may increase the hypotensive activities of Bupranolol.Experimental
HexamethoniumBupranolol may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalThe serum concentration of Bupranolol can be decreased when it is combined with Hexobarbital.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Bupranolol.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Bupranolol.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Bupranolol.Experimental
HydralazineHydralazine may increase the hypotensive activities of Bupranolol.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Bupranolol.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Bupranolol.Approved, Investigational
HydroxychloroquineThe metabolism of Bupranolol can be decreased when combined with Hydroxychloroquine.Approved
IbuprofenIbuprofen may decrease the antihypertensive activities of Bupranolol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Bupranolol.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Bupranolol.Approved
IloprostIloprost may increase the hypotensive activities of Bupranolol.Approved, Investigational
ImidaprilBupranolol may increase the hypotensive activities of Imidapril.Investigational
Imidazole salicylateImidazole salicylate may decrease the antihypertensive activities of Bupranolol.Experimental
IndacaterolBupranolol may decrease the bronchodilatory activities of Indacaterol.Approved
IndalpineThe serum concentration of Bupranolol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the hypotensive activities of Bupranolol.Approved
IndenololBupranolol may increase the hypotensive activities of Indenolol.Withdrawn
IndobufenIndobufen may decrease the antihypertensive activities of Bupranolol.Investigational
IndomethacinIndomethacin may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Bupranolol.Withdrawn
IndoraminBupranolol may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Insulin PorkBupranolol may increase the hypoglycemic activities of Insulin Pork.Approved
IpidacrineIpidacrine may increase the bradycardic activities of Bupranolol.Experimental
IproclozideIproclozide may increase the hypotensive activities of Bupranolol.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Bupranolol.Withdrawn
IrbesartanIrbesartan may increase the hypotensive activities of Bupranolol.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Bupranolol.Approved
IsoetarineBupranolol may decrease the bronchodilatory activities of Isoetarine.Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Bupranolol.Approved, Investigational, Withdrawn
IsoprenalineBupranolol may decrease the bronchodilatory activities of Isoprenaline.Approved
IsoxicamIsoxicam may decrease the antihypertensive activities of Bupranolol.Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Bupranolol.Approved
KebuzoneKebuzone may decrease the antihypertensive activities of Bupranolol.Experimental
KetanserinKetanserin may increase the hypotensive activities of Bupranolol.Investigational
KetoprofenKetoprofen may decrease the antihypertensive activities of Bupranolol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Bupranolol.Approved
LabetalolBupranolol may increase the orthostatic hypotensive activities of Labetalol.Approved
LacidipineBupranolol may increase the hypotensive activities of Lacidipine.Approved, Investigational
Lanatoside CBupranolol may increase the bradycardic activities of Lanatoside C.Experimental
LatanoprostLatanoprost may increase the hypotensive activities of Bupranolol.Approved, Investigational
LeflunomideLeflunomide may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Bupranolol.Approved, Investigational
LevomilnacipranThe serum concentration of Bupranolol can be increased when it is combined with Levomilnacipran.Approved
LevonordefrinLevonordefrin may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
LevosalbutamolBupranolol may decrease the bronchodilatory activities of Levosalbutamol.Approved
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Bupranolol.Approved, Vet Approved
LinsidomineBupranolol may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilLisinopril may increase the hypotensive activities of Bupranolol.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Bupranolol.Investigational
LobelineThe risk or severity of adverse effects can be increased when Bupranolol is combined with Lobeline.Investigational
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved, Investigational
LonazolacLonazolac may decrease the antihypertensive activities of Bupranolol.Experimental
LornoxicamLornoxicam may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
LosartanLosartan may increase the hypotensive activities of Bupranolol.Approved
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
MacitentanBupranolol may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Bupranolol.Approved
MalathionMalathion may increase the bradycardic activities of Bupranolol.Approved, Investigational
ManidipineBupranolol may increase the hypotensive activities of Manidipine.Approved, Investigational
MasoprocolMasoprocol may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Bupranolol.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Bupranolol.Approved
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Bupranolol.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Bupranolol.Approved
MefloquineMefloquine may increase the bradycardic activities of Bupranolol.Approved
MeloxicamMeloxicam may decrease the antihypertensive activities of Bupranolol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Bupranolol.Approved, Investigational
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Bupranolol.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Bupranolol.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Bupranolol.Approved, Investigational
MetahexamideBupranolol may increase the hypoglycemic activities of Metahexamide.Experimental
MetamizoleMetamizole may decrease the antihypertensive activities of Bupranolol.Investigational, Withdrawn
MethacholineThe risk or severity of adverse effects can be increased when Bupranolol is combined with Methacholine.Approved
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Bupranolol.Investigational
MethohexitalThe serum concentration of Bupranolol can be decreased when it is combined with Methohexital.Approved
MethoserpidineBupranolol may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Bupranolol.Approved
Methyl salicylateMethyl salicylate may increase the bradycardic activities of Bupranolol.Approved, Vet Approved
MethyldopaMethyldopa may increase the hypotensive activities of Bupranolol.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Bupranolol.Approved, Investigational
MethylergometrineBupranolol may increase the vasoconstricting activities of Methylergometrine.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
MethylphenobarbitalThe serum concentration of Bupranolol can be decreased when it is combined with Methylphenobarbital.Approved
MetildigoxinBupranolol may increase the bradycardic activities of Metildigoxin.Experimental
MetipranololMetipranolol may increase the hypotensive activities of Bupranolol.Approved
MetoclopramideMetoclopramide may increase the bradycardic activities of Bupranolol.Approved, Investigational
MetolazoneMetolazone may increase the hypotensive activities of Bupranolol.Approved
MetoprololMetoprolol may increase the hypotensive activities of Bupranolol.Approved, Investigational
MetyrosineBupranolol may increase the hypotensive activities of Metyrosine.Approved
MibefradilMibefradil may increase the hypotensive activities of Bupranolol.Investigational, Withdrawn
MidodrineBupranolol may increase the bradycardic activities of Midodrine.Approved
MilnacipranThe serum concentration of Bupranolol can be increased when it is combined with Milnacipran.Approved
MinaprineMinaprine may increase the bradycardic activities of Bupranolol.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Bupranolol.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Bupranolol.Investigational
MizoribineMizoribine may decrease the antihypertensive activities of Bupranolol.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Bupranolol.Approved
MoexiprilMoexipril may increase the hypotensive activities of Bupranolol.Approved
MofebutazoneMofebutazone may decrease the antihypertensive activities of Bupranolol.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Bupranolol.Approved, Investigational
MoricizineMoricizine may increase the hypotensive activities of Bupranolol.Approved, Investigational, Withdrawn
MoxonidineMoxonidine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved, Investigational
MuzolimineBupranolol may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Bupranolol.Approved
NabumetoneNabumetone may decrease the antihypertensive activities of Bupranolol.Approved
NadololNadolol may increase the hypotensive activities of Bupranolol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Bupranolol.Approved
NaftopidilBupranolol may increase the hypotensive activities of Naftopidil.Investigational
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Bupranolol.Approved, Vet Approved
NebivololNebivolol may increase the hypotensive activities of Bupranolol.Approved, Investigational
NefazodoneThe serum concentration of Bupranolol can be increased when it is combined with Nefazodone.Approved, Withdrawn
NeostigmineNeostigmine may increase the bradycardic activities of Bupranolol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Bupranolol.Approved
NialamideNialamide may increase the hypotensive activities of Bupranolol.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Bupranolol.Approved
NicorandilBupranolol may increase the hypotensive activities of Nicorandil.Approved, Investigational
NicotineThe risk or severity of adverse effects can be increased when Bupranolol is combined with Nicotine.Approved
NifedipineNifedipine may increase the hypotensive activities of Bupranolol.Approved
NifenazoneNifenazone may decrease the antihypertensive activities of Bupranolol.Experimental
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Bupranolol.Approved
NiguldipineBupranolol may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineNilvadipine may increase the hypotensive activities of Bupranolol.Approved, Investigational
NimesulideNimesulide may decrease the antihypertensive activities of Bupranolol.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Bupranolol.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Bupranolol.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Bupranolol.Approved, Investigational
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Bupranolol.Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Bupranolol.Approved
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
ObinutuzumabBupranolol may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Bupranolol.Withdrawn
OleandrinBupranolol may increase the bradycardic activities of Oleandrin.Experimental, Investigational
OlmesartanOlmesartan may increase the hypotensive activities of Bupranolol.Approved, Investigational
OlodaterolBupranolol may decrease the bronchodilatory activities of Olodaterol.Approved
OlopatadineOlopatadine may decrease the antihypertensive activities of Bupranolol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Bupranolol.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Bupranolol.Investigational
OrciprenalineBupranolol may decrease the bronchodilatory activities of Orciprenaline.Approved
OrgoteinOrgotein may decrease the antihypertensive activities of Bupranolol.Vet Approved
OuabainBupranolol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Bupranolol.Approved
OxprenololOxprenolol may increase the hypotensive activities of Bupranolol.Approved
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Bupranolol.Approved, Withdrawn
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
ParaoxonParaoxon may increase the bradycardic activities of Bupranolol.Experimental
ParecoxibParecoxib may decrease the antihypertensive activities of Bupranolol.Approved
PargylinePargyline may increase the hypotensive activities of Bupranolol.Approved
ParoxetineThe serum concentration of Bupranolol can be increased when it is combined with Paroxetine.Approved, Investigational
ParthenolideParthenolide may decrease the antihypertensive activities of Bupranolol.Investigational
PenbutololPenbutolol may increase the hypotensive activities of Bupranolol.Approved, Investigational
PentobarbitalThe serum concentration of Bupranolol can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Bupranolol.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Bupranolol.Approved, Investigational
PerazinePerazine may increase the hypotensive activities of Bupranolol.Investigational
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilPerindopril may increase the hypotensive activities of Bupranolol.Approved
PerphenazinePerphenazine may increase the hypotensive activities of Bupranolol.Approved
PeruvosideBupranolol may increase the bradycardic activities of Peruvoside.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Bupranolol.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Bupranolol.Withdrawn
PhenobarbitalThe serum concentration of Bupranolol can be decreased when it is combined with Phenobarbital.Approved
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Bupranolol.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Bupranolol.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Bupranolol.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Bupranolol.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved, Vet Approved, Withdrawn
PhysostigminePhysostigmine may increase the bradycardic activities of Bupranolol.Approved
PilocarpineThe risk or severity of adverse effects can be increased when Bupranolol is combined with Pilocarpine.Approved
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Bupranolol.Withdrawn
PindololPindolol may increase the hypotensive activities of Bupranolol.Approved
PirbuterolBupranolol may decrease the bronchodilatory activities of Pirbuterol.Approved
PirfenidonePirfenidone may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Bupranolol.Approved
PiroxicamPiroxicam may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
PirprofenPirprofen may decrease the antihypertensive activities of Bupranolol.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Bupranolol.Withdrawn
PolythiazidePolythiazide may increase the hypotensive activities of Bupranolol.Approved
PranoprofenPranoprofen may decrease the antihypertensive activities of Bupranolol.Experimental, Investigational
PrazosinBupranolol may increase the orthostatic hypotensive activities of Prazosin.Approved
PrimaquineThe metabolism of Bupranolol can be decreased when combined with Primaquine.Approved
PrimidoneThe serum concentration of Bupranolol can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcaterolBupranolol may decrease the bronchodilatory activities of Procaterol.Approved, Investigational
ProchlorperazineProchlorperazine may increase the hypotensive activities of Bupranolol.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the antihypertensive activities of Bupranolol.Experimental
PromazinePromazine may increase the hypotensive activities of Bupranolol.Approved, Vet Approved
PromethazinePromethazine may increase the hypotensive activities of Bupranolol.Approved
PropacetamolPropacetamol may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
PropafenoneThe serum concentration of Bupranolol can be increased when it is combined with Propafenone.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Bupranolol.Vet Approved
PropranololPropranolol may increase the hypotensive activities of Bupranolol.Approved, Investigational
PropyphenazonePropyphenazone may decrease the antihypertensive activities of Bupranolol.Experimental
ProquazoneProquazone may decrease the antihypertensive activities of Bupranolol.Experimental
ProscillaridinBupranolol may increase the bradycardic activities of Proscillaridin.Experimental
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
PTC299PTC299 may decrease the antihypertensive activities of Bupranolol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Bupranolol.Approved
QuinaprilQuinapril may increase the hypotensive activities of Bupranolol.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Bupranolol.Approved
RamiprilRamipril may increase the hypotensive activities of Bupranolol.Approved
RasagilineRasagiline may increase the hypotensive activities of Bupranolol.Approved
RegorafenibRegorafenib may increase the bradycardic activities of Bupranolol.Approved
RemifentanilRemifentanil may increase the bradycardic activities of Bupranolol.Approved
RemikirenRemikiren may increase the hypotensive activities of Bupranolol.Approved
RescinnamineBupranolol may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Bupranolol.Approved, Investigational
ResveratrolResveratrol may decrease the antihypertensive activities of Bupranolol.Approved, Experimental, Investigational
RifampicinThe serum concentration of Bupranolol can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Bupranolol can be decreased when it is combined with Rifapentine.Approved
RilmenidineRilmenidine may increase the hypotensive activities of Bupranolol.Investigational
RiociguatBupranolol may increase the hypotensive activities of Riociguat.Approved
RisperidoneRisperidone may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved, Investigational
RitodrineBupranolol may decrease the bronchodilatory activities of Ritodrine.Approved, Investigational
RituximabBupranolol may increase the hypotensive activities of Rituximab.Approved
RivastigmineRivastigmine may increase the bradycardic activities of Bupranolol.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Bupranolol.Investigational, Withdrawn
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved, Investigational
SafrazineSafrazine may increase the hypotensive activities of Bupranolol.Withdrawn
SalbutamolBupranolol may decrease the bronchodilatory activities of Salbutamol.Approved, Vet Approved
SalicylamideSalicylamide may decrease the antihypertensive activities of Bupranolol.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Bupranolol.Approved, Vet Approved
SalmeterolBupranolol may decrease the bronchodilatory activities of Salmeterol.Approved
SalsalateSalsalate may decrease the antihypertensive activities of Bupranolol.Approved
SaprisartanSaprisartan may increase the hypotensive activities of Bupranolol.Experimental
SecobarbitalThe serum concentration of Bupranolol can be decreased when it is combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Bupranolol.Approved, Investigational, Vet Approved
SelexipagBupranolol may increase the hypotensive activities of Selexipag.Approved
SemapimodSemapimod may decrease the antihypertensive activities of Bupranolol.Investigational
SeratrodastSeratrodast may decrease the antihypertensive activities of Bupranolol.Approved
SerrapeptaseSerrapeptase may decrease the antihypertensive activities of Bupranolol.Investigational
SertralineThe serum concentration of Bupranolol can be increased when it is combined with Sertraline.Approved
SildenafilSildenafil may increase the antihypertensive activities of Bupranolol.Approved, Investigational
SilodosinBupranolol may increase the orthostatic hypotensive activities of Silodosin.Approved
SitaxentanBupranolol may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SpiraprilSpirapril may increase the hypotensive activities of Bupranolol.Approved
SRT501SRT501 may decrease the antihypertensive activities of Bupranolol.Investigational
SufentanilSufentanil may increase the bradycardic activities of Bupranolol.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Bupranolol.Approved
SulindacSulindac may decrease the antihypertensive activities of Bupranolol.Approved
SuprofenSuprofen may decrease the antihypertensive activities of Bupranolol.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the antihypertensive activities of Bupranolol.Experimental
TacrineTacrine may increase the bradycardic activities of Bupranolol.Investigational, Withdrawn
TadalafilTadalafil may increase the antihypertensive activities of Bupranolol.Approved, Investigational
TalinololBupranolol may increase the hypotensive activities of Talinolol.Investigational
TamsulosinBupranolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
TarenflurbilTarenflurbil may decrease the antihypertensive activities of Bupranolol.Investigational
TelmisartanTelmisartan may increase the hypotensive activities of Bupranolol.Approved, Investigational
TemocaprilBupranolol may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenidapTenidap may decrease the antihypertensive activities of Bupranolol.Experimental
TenoxicamTenoxicam may decrease the antihypertensive activities of Bupranolol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Bupranolol.Vet Approved
TerazosinBupranolol may increase the orthostatic hypotensive activities of Terazosin.Approved
TerbutalineBupranolol may decrease the bronchodilatory activities of Terbutaline.Approved
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Bupranolol.Approved
TerlipressinTerlipressin may increase the hypotensive activities of Bupranolol.Approved, Investigational
TetrahydropalmatineBupranolol may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TheodrenalineBupranolol may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineBupranolol may decrease the bronchodilatory activities of Theophylline.Approved
ThiamylalThe serum concentration of Bupranolol can be decreased when it is combined with Thiamylal.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Bupranolol.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Bupranolol.Withdrawn
ThiopentalThe serum concentration of Bupranolol can be decreased when it is combined with Thiopental.Approved, Vet Approved
ThioridazineThioridazine may increase the hypotensive activities of Bupranolol.Approved, Withdrawn
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Bupranolol.Approved
TiboloneBupranolol may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenTicrynafen may increase the hypotensive activities of Bupranolol.Withdrawn
TimololTimolol may increase the hypotensive activities of Bupranolol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Bupranolol.Investigational
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
TolazamideBupranolol may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineTolazoline may increase the hypotensive activities of Bupranolol.Approved, Vet Approved
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Bupranolol.Approved
TolmetinTolmetin may decrease the antihypertensive activities of Bupranolol.Approved
TolonidineBupranolol may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Bupranolol.Approved
TorasemideTorasemide may increase the hypotensive activities of Bupranolol.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Bupranolol.Approved
TranilastTranilast may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Bupranolol.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Bupranolol.Approved
TravoprostTravoprost may increase the hypotensive activities of Bupranolol.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Bupranolol.Approved, Investigational
TribenosideTribenoside may decrease the antihypertensive activities of Bupranolol.Experimental
TrichlorfonTrichlorfon may increase the bradycardic activities of Bupranolol.Vet Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Bupranolol.Approved, Vet Approved
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Bupranolol.Approved
TriflupromazineTriflupromazine may increase the hypotensive activities of Bupranolol.Approved, Vet Approved
TrimazosinBupranolol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Bupranolol.Approved, Investigational
TriptolideTriptolide may decrease the antihypertensive activities of Bupranolol.Investigational
TubocurarineTubocurarine may increase the bradycardic activities of Bupranolol.Approved
UdenafilUdenafil may increase the antihypertensive activities of Bupranolol.Approved, Investigational
UnoprostoneUnoprostone may increase the hypotensive activities of Bupranolol.Approved
UrapidilBupranolol may increase the orthostatic hypotensive activities of Urapidil.Investigational
ValdecoxibValdecoxib may decrease the antihypertensive activities of Bupranolol.Investigational, Withdrawn
ValsartanValsartan may increase the hypotensive activities of Bupranolol.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Bupranolol.Approved
VareniclineThe risk or severity of adverse effects can be increased when Bupranolol is combined with Varenicline.Approved, Investigational
VenlafaxineThe serum concentration of Bupranolol can be increased when it is combined with Venlafaxine.Approved
VerapamilVerapamil may increase the hypotensive activities of Bupranolol.Approved
VilanterolBupranolol may decrease the bronchodilatory activities of Vilanterol.Approved
VincamineBupranolol may increase the hypotensive activities of Vincamine.Experimental
VinpocetineBupranolol may increase the hypotensive activities of Vinpocetine.Investigational
XipamideBupranolol may increase the hypotensive activities of Xipamide.Experimental
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Bupranolol.Approved, Vet Approved
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Bupranolol.Approved, Investigational
ZileutonZileuton may decrease the antihypertensive activities of Bupranolol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Bupranolol can be increased when it is combined with Zimelidine.Withdrawn
ZofenoprilBupranolol may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracZomepirac may decrease the antihypertensive activities of Bupranolol.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference

Kunz, W., Jacobi, H., Koch, C. and Geus, R.J.; U.S. Patent 3,309,406; March 14, 1967.

General References
Not Available
External Links
Human Metabolome Database
HMDB15697
KEGG Drug
D07590
PubChem Compound
2475
PubChem Substance
99445278
ChemSpider
2381
BindingDB
25765
ChEBI
135123
ChEMBL
CHEMBL305380
PharmGKB
PA165958426
IUPHAR
550
Guide to Pharmacology
GtP Drug Page
ATC Codes
C07AA19 — Bupranolol

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.143 mg/mLALOGPS
logP3.14ALOGPS
logP2.99ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)14.09ChemAxon
pKa (Strongest Basic)9.76ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area41.49 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity74.86 m3·mol-1ChemAxon
Polarizability30.35 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9784
Blood Brain Barrier-0.7572
Caco-2 permeable+0.5576
P-glycoprotein substrateSubstrate0.6384
P-glycoprotein inhibitor INon-inhibitor0.6857
P-glycoprotein inhibitor IINon-inhibitor0.8993
Renal organic cation transporterNon-inhibitor0.8713
CYP450 2C9 substrateNon-substrate0.8011
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.6373
CYP450 1A2 substrateInhibitor0.5416
CYP450 2C9 inhibitorNon-inhibitor0.8165
CYP450 2D6 inhibitorInhibitor0.6045
CYP450 2C19 inhibitorNon-inhibitor0.7218
CYP450 3A4 inhibitorNon-inhibitor0.8424
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5726
Ames testNon AMES toxic0.9025
CarcinogenicityNon-carcinogens0.8249
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.4441 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9455
hERG inhibition (predictor II)Non-inhibitor0.6443
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenol ethers
Sub Class
Not Available
Direct Parent
Phenol ethers
Alternative Parents
Phenoxy compounds / Toluenes / Chlorobenzenes / Alkyl aryl ethers / Aryl chlorides / Secondary alcohols / 1,2-aminoalcohols / Dialkylamines / Organopnictogen compounds / Organochlorides
show 1 more
Substituents
Phenoxy compound / Phenol ether / Alkyl aryl ether / Toluene / Chlorobenzene / Halobenzene / Aryl chloride / Aryl halide / Monocyclic benzene moiety / 1,2-aminoalcohol
show 15 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
References
  1. Zelaszczyk D, Kozlowska H, Baranowska U, Baranowska M, Reutelsterz A, Kiec-Kononowicz K, Malinowska B, Schlicker E: Four close bupranolol analogues are antagonists at the low-affinity state of beta1-adrenoceptors. J Physiol Pharmacol. 2009 Mar;60(1):51-60. [PubMed:19439807]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
Gene Name
ADRB2
Uniprot ID
P07550
Uniprot Name
Beta-2 adrenergic receptor
Molecular Weight
46458.32 Da
References
  1. Lenard NR, Gettys TW, Dunn AJ: Activation of beta2- and beta3-adrenergic receptors increases brain tryptophan. J Pharmacol Exp Ther. 2003 May;305(2):653-9. Epub 2003 Jan 24. [PubMed:12606631]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. Beta-3 is involved in the regulation of lipolysis and thermogenesis.
Gene Name
ADRB3
Uniprot ID
P13945
Uniprot Name
Beta-3 adrenergic receptor
Molecular Weight
43518.615 Da
References
  1. Lenard NR, Gettys TW, Dunn AJ: Activation of beta2- and beta3-adrenergic receptors increases brain tryptophan. J Pharmacol Exp Ther. 2003 May;305(2):653-9. Epub 2003 Jan 24. [PubMed:12606631]
  2. Matsushita M, Horinouchi T, Tanaka Y, Tsuru H, Koike K: Characterization of beta 3-adrenoceptor-mediated relaxation in rat abdominal aorta smooth muscle. Eur J Pharmacol. 2003 Dec 15;482(1-3):235-44. [PubMed:14660028]

Drug created on October 20, 2010 15:45 / Updated on November 09, 2017 04:40